TrialNature communications2025

Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO).

Peiyuan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.